Icu Medical, Inc. · NASDAQ:ICUI
Icu Medical — Investor Presentation (January 2015)
20 slides from Icu Medical's investor presentation, January 2015
Slide 1: ICU Medical, Inc. Investor Presentation (NASDAQ:ICUI)
ICU Medical, Inc. Investor Presentation (NASDAQ:ICUI) January 2015 1
Slide 2: Forward Looking Statement
Forward Looking Statement > Any statement concerning Management’s expectation with respect to future results is a forward looking statement based upon the best information currently available to Management and assumptions Management believes are reasonable, but Management does not intend the stateme
Slide 3: ICU Medical At-a-Glance
ICU Medical At-a-Glance > We are a $300M+ revenue publicly traded global medical device company (NASDAQ: ICUI) developing differentiated products and technologies addressing unmet clinical needs in three market segments: Industry leading needlefree IV connector Needlefree closed system transfer devi
Slide 4: Reasons to Consider Investing
Reasons to Consider Investing > High percentage of sticky, recurring revenues Overview > Positioned for near-term EPS and cash flow growth and long-term revenue growth > Share Price (01/09/15) $84.15 > International growth opportunities are increasing due to adoption of technology and evolving > Sha
Slide 5: ICU Medical Revenues & Gross Margin
ICU Medical Revenues & Gross Margin Revenue $ Gross Margin % 350 50% $317 $314 $305 $302 49% 49% 300 45% 47% 46% US Dollars in Millions 250 $132 $124 $108 $126 40% 200 $75 $79 35% $67 $69 150 30% 100 $116 $115 $118 $109 50 25% 0 20% 2011 2012 2013 2014 Est 2011 2012 2013 2014 Est Dom Direct Int Dire
Slide 6: Value Creation Drivers
Value Creation Drivers > Implemented operational improvements across variety of cost drivers to yield at least $10 million of SG&A improvements in FY15 versus FY14 > Focus on improved domestic commercial execution > Continue international investments to drive growth in proprietary IV connectors and
Slide 7: IV Therapy Solutions
IV Therapy Solutions > MORE THAN 90% of hospitalized patients receive IV therapy during their hospital stay. For this, ICU Medical provides: The world’s most The world’s most complete line of complete line of standard needlefree IV connectors and custom IV sets IV Connector & Sets $2 Billion+ Worldw
Slide 8: Connector Design Drives Clinical Value
Connector Design Drives Clinical Value > Clinically-proven design features work together to provide a safe and effective microbial barrier helping keep patients safer from bloodstream infections—a major non-reimbursable expense to hospitals > Three distinct connectors with a unique set of clinical b
Slide 9: IV Therapy Solutions
IV Therapy Solutions > Custom and Standard Set Capabilities. Broadly deploying our market- leading connector technology in a wide range of stock and custom IN sets and kits. From high-volume standard sets to highly complex custom sets, ICU Medical’s sophisticated operational efficiencies and proprie
Slide 10: IV Therapy Revenues
IV Therapy Revenues $250 $225 $220 $208 $119 $214 $109 $200 $115 $96 US Dollars in Millions $150 $111 $116 $100 $106 $93 $50 $0 2011 2012 2013 2014 Est ICU Direct OEM 10
Slide 11: Critical Care Solutions
Critical Care Solutions > Hemodynamic Monitoring Systems and Disposables Used in Acute Care Settings to Measure a Patient's Cardiovascular Status > Specialized area of monitoring—we do not compete with multiparameter monitoring companies > Razor/razor blade business model. ICU Medical disposables us
Slide 12: Critical Care Business Overview
Critical Care Business Overview > Acquired the former Abbott Critical Care business from Hospira in 2009 (including Salt Lake City manufacturing) > Created Critical Care Division with senior-level management and enhanced marketing/sales support in July 2014 > Margin improvement initiatives: performi
Slide 13: Critical Care Revenues
Critical Care Revenues 70 60 $64 $59 50 $54 $54 US Dollars in Millions 40 30 20 10 0 2011 2012 2013 2014 Est 13
Slide 14: Oncology Solutions
Oncology Solutions > The world’s most comprehensive IV medication safe handling systems designed to keep pharmacists, nurses, and patients safe from exposure to hazardous drugs used in chemotherapy during preparation, transportation, administration, and disposal. Closed System Transfer Devices (CSTD
Slide 15: Positive Market Trends Driving CSTDs
Positive Market Trends Driving CSTDs Growing Awareness, Mounting Support/Evidence for the need for CSTD’s > State Legislation – WA, CA, NC (passed) – MD(filed, pending) > USP Chapter Update • USP <800> Proposed New Chapter > Includes Administration > CSTD shall be used during administration > FDA ON
Slide 16: Oncology Revenues
Oncology Revenues $40 $38 $37 $35 $15 $12 $30 $30 $13 $24 US Dollars in Millions $25 $11 $25 $20 $23 $15 $17 $10 $13 $5 $0 2011 2012 2013 2014 Est ICU Direct OEM 16
Slide 17: ICU Medical Global Manufacturing
ICU Medical Global Manufacturing > World-class molding, automation, and custom set assembly processes Salt Lake City, UT > 1,900+ operations employees worldwide > 100% paperless production 450,000 Square Feet Molding/Automation > Capital expenditures declining, most capacity/automation investments h
Slide 18: Management Team
Management Team > Vivek Jain – CEO, 11 months, CareFusion/Cardinal, JP Morgan > Scott Lamb – CFO, 11 years, GE, various start-ups > Alison Burcar – VP/GM Infusion Systems, 19 years > Steve Riggs – VP Operations, 22 years > Greg Pratt – VP Sales, 18 years > Tom McCall – VP/GM Critical Care, 4 years,
Slide 19: Financials
Financials Revenue Margins 350 0.5 300 49.4% 49.3% 49.0% $317 47.1% $302 $314 $305 0.4 US Dollars in Millions 250 200 0.3 150 0.2 100 0.1 50 0 0 2011 2012 2013 2014 Est 2011 2012 2013 2014 Est Adjusted EBITDA Cash & Investments 100 400 350 80 $86 300 $345 US Dollars in Millions $79 US Dollars in Mil
Slide 20: ICU Medical, Inc. Investor Presentation (NASDAQ:ICUI)
ICU Medical, Inc. Investor Presentation (NASDAQ:ICUI) January 2015 20